AIMM Therapeutics Appoints Former Head Novartis Research Institutes Jan de Vries CEO, and John Womelsdorf VP Business

  AIMM Therapeutics Appoints Former Head Novartis Research Institutes Jan de
  Vries CEO, and John Womelsdorf VP Business Development

Business Wire

AMSTERDAM -- November 08, 2012

AIMM Therapeutics, a next generation antibody company co-founded by Hergen
Spits, PhD, today announced the appointment of Jan de Vries, PhD, as Chief
Executive Officer and John Womelsdorf, PhD, as Vice President Business
Development. Capitalizing on its proprietary technology to immortalize and
select B cells of individuals who produce antibodies with high therapeutic
value, AIMM Therapeutics has developed a state-of-the-art antibody technology
platform to develop high affinity human monoclonal antibodies. Three of its
infectious diseases programs are already partnered with top tier
pharmaceutical companies. Building on its successful track record to date and
under Dr. de Vries’s leadership, the company will further expand into cancer
indications and inflammatory and autoimmune diseases.

Tom Schwarz, Chairman, said, “Jan de Vries has deep experience in drug
discovery and early development and was involved in developing many
successful, currently marketed drugs. We are pleased to have attracted him to
lead AIMM Therapeutics, as the company transitions to become one of the major
players in the next-generation antibody space.”

Jan de Vries, CEO, said, “AIMM has succeeded in establishing a platform that
yields high quality first-in-class antibodies that are coveted by big pharma.
I look forward to further building the company and leading the effort to
branch out into other therapeutic areas together with John Womelsdorf and the
team.”

Dr. de Vries has over 25 years of pharmaceutical industry experience in
discovery and early development. He was Head of the Novartis Research
Institutes for Biomedical Research in Basel, Switzerland, and Global Head of
the Disease Area Autoimmunity, Transplantation and Inflammation. At Novartis,
he was instrumental in developing many drugs including Ilaris (Canakinumab),
Secukinumab, Elidel, and Gilenya. Prior to that he was at DNAX Research
Institute of Molecular Biological Research in Palo Alto, California where he
co-discovered IL-4, IL-10 and IL-13. Dr. de Vries started his career in
academia at the Netherlands Cancer Institute, where he was Head of the
Department of Immunology.

Dr. Womelsdorf has more than 16 years of experience in high profile business
development roles at Optimer Pharmaceuticals, Cyclacel Pharmaceuticals, J&J,
Roche, and Baxter International, with a large number of successful partnering
and licensing agreements to his name.

About AIMM Therapeutics

AIMM Therapeutics (AIMM) is a leading antibody company that based on its
synergistic, state-of-the-art antibody technology platform develops high
affinity human monoclonal antibodies from immortalized and selected B cells of
individuals who produce antibodies with high therapeutic value. AIMM
antibodies can be further affinity matured in a proprietary process that does
not require molecular engineering. AIMM has a broad product pipeline targeted
at pathogenic viruses and bacteria, and is expanding its pipeline with drug
candidates for cancer and inflammatory diseases. For more information:
www.aimmtherapeutics.com

Contact:

For further enquiries
AIMM Therapeutics
Jan de Vries, +1 858-405-1356
CEO
jdevries@aimmtherapeutics.com
or
Capricorn One
Hans Herklots, +41 79 598 7149
Managing Director
capricorn1@bluewin.ch
 
Press spacebar to pause and continue. Press esc to stop.